29
Disunity before the EPO AIPLA Biotechnology committee March 17 th , 2011 Simon Wright BSc EPA CPA [email protected] www.jakemp.com

Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA [email protected]

Embed Size (px)

Citation preview

Page 1: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity before the EPOAIPLA Biotechnology committee

March 17th, 2011

Simon Wright BSc EPA CPA

[email protected]

www.jakemp.com

Page 2: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Main topics

• EPO law on disunity/restriction practice

• Differences from US PTO practice

• Procedural implications and practical tips

• Changes in timing of divisionals

Page 3: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice (1)

• EP patent application must relate to one invention or “group of inventions so linked to form a single inventive concept” (Art. 82) EPC

• There must be one or more “special technical features” which “define a contribution…over the prior art” (Rule 44)

Page 4: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice (2)

• Rules demand that the independent claims must have at least one common novel feature

• In practice this linking feature needs to provide patentability over the closest prior art, i.e. both novelty and non-obviousness

Page 5: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice (3)

• As a guide, the following groups are unitary:– a product– a process adapted to make that product– use of that product; and– apparatus specifically designed to conduct the

process

Page 6: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice (4)

• EPO sees inventions in terms of the protein or nucleotide sequence (so each protein is a different invention)

• For each protein (or product), if new, one can claim:– Protein per se

– Uses of the protein (medical or otherwise)

– Manufacture of the protein

– Products comprising or encoding protein (vectors, etc.)

Page 7: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice (5)

• Contrast with US PTO• EPO regards “concept” as the heart of the

invention (e.g. each protein)• US PTO regards each category (product,

use, process, etc.) as different inventions• But the US PTO may regard different

proteins in same category (e.g. product) as the same invention

Page 8: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice - example

• 3 proteases A, B and C – try to draft novel generic claim covering all 3 proteases (e.g. all have common novel feature, such as same mutation or internal domain, or novel property/function)

• For all 3 proteases, can claim:– Protease itself, nucleotide encoding protease,

compositions comprising protease or DNA, medical uses of both, manufacture of both, inhibitors of protease (e.g. antibodies), so downstream products

Page 9: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice - example• 3 proteases A, B and C – no common novel feature,

e.g. each has different mutation, so disunity• For protease A, can claim:

– Protease A, nucleotide encoding protease A, compositions comprising protease or DNA, medical uses of both, manufacture of both, inhibitors of protease (e.g. antibodies), so downstream products

• File divisionals to proteases B and C• US PTO may regard A, B and C as same invention

but only products allowed in same case• In the US, file divisionals to uses, etc.

Page 10: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Disunity practice

• Disunity a priori, e.g. clearly unrelated protein and antibody

• Disunity a posteriori, e.g. after searching• Prior art destroys novelty of claim, so no common

linking feature, or the common link is no longer novel – more likely and increasingly common

• The art thus fragments the claim into different inventions - EPO will only search the first invention as defined in the claims – often highly unpredictable splitting of matter by Examiner

Page 11: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Procedure (1)• At the search stage, there is no mechanism for

traversing disunity• EPO will only search 1st invention, as defined in

dependent claims, and only searched matter can be examined

• Now get search opinion (like 1st Office Action) at search stage, earlier engagement with Examiner

• Only during substantive examination can you traverse disunity

• Can appeal, attend hearing (but Examiner will have conducted earlier search so reversal difficult)

Page 12: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Procedure (2)

• Significant difference between – convention (not ex-PCT) and divisional

applications (where one can pay for additional searches – usually a 1 month term); and

– Ex-PCT applications (no longer possible to pay additional search fees)

• EPC 2000, came into force December 2007

Page 13: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Procedure – for ex-PCT cases (3)

• US PTO was ISA• EPO will carry out search for first invention

claimed. No opportunity for further searching• Can only “elect” the first invention for further

prosecution, i.e. EPO will only examine the first (and searched) invention

• Re-order claims on EP phase entry to place most important invention first

• EPO search can be on a different invention from the US PTO!

Page 14: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Procedure – for ex-PCT cases (4)

• EPO was ISA• No further searching by EPO• Substantive examination only on matter

searched in Int’l phase and covered by ISR• So pay additional search fees in Int’l phase?• Delete unsearched claims to save costs (and

pursue in a divisional?)• Next time, don’t elect EPO as the ISA!

Page 15: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

New restrictions and objections at search stage - 1

• The EPO Search Examiner will now object if:- R62a: there are multiple independent claims in the

same claim category (apparatus, method etc.); and/or(These are only allowed if claims are to:– plurality of inter-related products– different uses of a product or apparatus– different solutions to same problem where not appropriate to cover a

single independent claim)

- R63: the claims fail to meet the requirements of the EPC such that they are unsearchable

Page 16: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Restrictions or objections at search stage - 2

• Applicant gets opportunity to indicate the subject matter to be searched if either or both objections raised – 2 month non-extendable term set

• If matter to be searched is not indicated or clarified then the EPO will search first independent claim in each claim category or, in case of R63, may declare the claims unsearchable

• Will carry on restricting search if lack of unity too

Page 17: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Restrictions or objections at search stage - 3

• EPO legislation now requires applicant to limit to searched subject matter during examination

• Cannot amend to (re)introduce unsearched subject matter

• Applicants therefore advised to get claims into “searchable” shape on filing, to avoid restrictions on searched subject matter

• Restricted searches can waste claims fees!

Page 18: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Practical Tips (1)

• Try to draft generic claims with lots of intermediate generalisations (fallback positions) for maximum flexibility and to keep unity

• Identify common features present in the proteins/DNA/antibodies of the invention, etc. and claim those

• Anticipate objections and the art (conduct searches before filing)

• Place most important embodiments first in the claims

• File several applications at the outset?

Page 19: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Practical Tips – (2)

When entering EP regional phase:• EPO will only search one invention, therefore

identify novel and potentially inventive unified claim strings and limit to those

• Place most important invention first• Avoid R62a restriction by amending claims to have

one independent claim per category• Delete plainly disunified inventions? If so, pursue

these in a divisional • Amend/compact claims down to 15 (claims fee is

210 EUR for each claim above 15)

Page 20: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisional Applications – 1

• New 2 year time limit for divisional applications

• Limits applicant’s ability to file “voluntary” divisionals later in prosecution

• Intended to improve legal certainty for third parties and reduce EPO’s workload

• Counters alleged “abuse” by applicants

Page 21: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisional Applications – 2Previous EPO practice• Applicant can file a divisional application

from any pending earlier European Patent application– Division may be voluntary or in response to

lack of unity– Divisionals from divisionals – “cascade”

allowed (this has been controversial)– Divisional may be filed at any time before

grant, lapse or refusal of immediate parent

Page 22: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisional Applications – 3New Rules• Before grant, lapse or refusal but also before: “24 months from the Examining Division’s first

communication in respect of the earliest application for which a communication has been issued” – voluntary division

• No extensions of time or further processing• Deadline applies to whole patent family, i.e. any

divisionals of divisionals must also be filed within 24 month term set by earliest application

Page 23: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisional Applications – 4New Rules• …or 24 months from an Examining Division

communication raising a new objection of lack of unity – mandatory division

• Doubt over what is a “new” lack of unity objection

• Allows for late division in response to new lack of unity – but likely to be rare

• Can only divide the application objected to• No extensions of time or further processing

Page 24: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisionals - Example 1

• First exam report issues 1 May 2010 objecting to lack of unity – inventions A and B– Any divisionals must be filed by 1 May 2012

• Limit to A and file divisional application to B• Exam report on divisional ‘B’ issues 1 September

2012 with new lack of unity objection – inventions B1 and B2– Divisional applications can now be filed (only for

invention B1 or B2) up to 1 September 2014

Page 25: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisionals – Example 2

• First exam report issues 1 May 2010 with objection of lack of unity – inventions A, B & C– All divisionals must be filed before 1 May 2012

• Limit to A and file one divisional to B & C• Exam report on divisional ‘B & C’ issues 1 Sept

2012 with disunity objection to inventions B & C– Not a new objection of lack of unity so previous

deadline stands. Now too late to divide further, so ALL divisionals should have been filed by 1 May 2012

Page 26: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisionals – Alternative tack?

• Alternatively, applicant proactively removes B & C before unity objected to

• Same 1 May 2012 divisional filing deadline• File a voluntary divisional to B and C before then• When disunity objection raised on divisional (even

if after May 2012) a fresh 2 year term is set for dividing out B or C

• Need for second divisional has probably been delayed beyond May 2012

• May be problems though…

Page 27: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Divisional Applications

Can one “Engineer” a new unity objection, e.g. by adding new non-unified claims during prosecution or when filing a divisional?

• Voluntary amendments now limited to response to search opinion

• Examiner’s discretion– whether to enter any amendment after first exam report– whether to raise an objection of lack of unity at all

• Examiner may not object to unity at all!• “Engineering” option is unpredictable & risky

Page 28: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Q&A

Thanks for listening in!

Simon Wright BSc EPA CPA [email protected]

www.jakemp.com

Page 29: Disunity before the EPO AIPLA Biotechnology committee March 17 th, 2011 Simon Wright BSc EPA CPA swright@jakemp.com

Many thanks to our sponsors!